Autologous stem cell transplantation for patients with amyloid light chain (AL) amyloidosis
Completed
- Conditions
- Amyloid light-chain (AL) amyloidosisNutritional, Metabolic, EndocrineAmyloidosis
- Registration Number
- ISRCTN01207094
- Lead Sponsor
- Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
1. Age 18-65 years incl.
2. Monoclonal Gammopathy of Undetermined Significance (MGUS), multiple myeloma stage I
3. Histologically documented systemic AL amyloidosis
4. Untreated or previously treated with maximal 3 courses of melphalan and prednisone
5. The patient must give informed consent according to the rules of the hospital
Exclusion Criteria
1. Prior malignancies diagnosed less than 5 years ago, except non-melanoma skin tumours or stage 0 (in situ) cervical carcinoma
2. Patients with familial variants of systemic amyloidosis
3. Severe pulmonary, neurologic, psychiatric, cardiac, liver or metabolic disease not related to AL amyloidosis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method